[Pexidartinib inhibits the aggregation of monocytes into tumor microenvironment and reduces the number of M2 tumor-associated macrophages].
Objective To explore the effect of pexidartinib on the recruitment of monocytes into the tumor microenvironment and the polarization of M2 macrophages. Methods The colon cancer mouse model was established with the subcutaneous rejection of MC38 cells. After the tumor-bearing mice were treated with pexidartinib, we observed the effects of pexidartinib on the tumor growth, the survival of tumor-bearing mouse and the number of intratumoral tumor-associated macrophages (TAMs). Peripheral blood mononuclear cells were isolated from the enhanced green fluorescent protein (EGFPTg/+) transgenic mice and then transferred into the tumor-bearing mice via tail vein. After the tumor-bearing mice were treated with pexidartinib, the monocyte recruitment and the proportions of F4/80 and CD206-positive cells were detected by the immunofluorescence and flow cytometry. Results Pexidartinib alleviated the growth of MC38 cells in vivo and improved the survival rate in tumor-bearing mice. Pexidartinib reduced the number of TAMs and the formation of M2 TAMs in the tumor microenvironment, and inhibited the recruitment of monocytes from peripheral blood to the tumor microenvironment. Conclusion Pexidartinib can inhibit the tumor growth by suppressing the aggregation of macrophages and the number of M2 TAMs in the tumor microenvironment.